Posted on 12/11/2009 in Pharmaceutical Company Product News Daiichi Sankyo has announced that its drug Welchol has been granted approval by the Food and Drug Administration (FDA) for use in heterozygous familial hypercholesterolemia patients attempting to lower their cholesterol levels.
The therapy has been approved as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol in boys and girls aged between the ages of ten and 17.
It can be taken alone or with a statin in those patients whose diet therapy has failed to prove effective.
Evan Stein, director of the Metabolic and Atherosclerosis Research Centre, stated: "The FDA approval of Welchol for children with inherited high cholesterol provides another important treatment option for these children, whose elevated LDL cholesterol puts them at increased risk of cardiovascular disease."
Last month, Daiichi Sankyo created a new subsidiary with Ranbaxy, which aims to produce products for the generic drugs market.
Other news stories from 12/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
